These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 16545770)

  • 1. Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9.
    Locuson CW; Gannett PM; Tracy TS
    Arch Biochem Biophys; 2006 May; 449(1-2):115-29. PubMed ID: 16545770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
    Hummel MA; Gannett PM; Aguilar JS; Tracy TS
    Biochemistry; 2004 Jun; 43(22):7207-14. PubMed ID: 15170358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity.
    Wei L; Locuson CW; Tracy TS
    Mol Pharmacol; 2007 Nov; 72(5):1280-8. PubMed ID: 17686967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore.
    Egnell AC; Eriksson C; Albertson N; Houston B; Boyer S
    J Pharmacol Exp Ther; 2003 Dec; 307(3):878-87. PubMed ID: 14557374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: the molecular basis of substrate binding and regioselectivity toward warfarin.
    Seifert A; Tatzel S; Schmid RD; Pleiss J
    Proteins; 2006 Jul; 64(1):147-55. PubMed ID: 16639745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrochemical characterisation of the human cytochrome P450 CYP2C9.
    Johnson DL; Lewis BC; Elliot DJ; Miners JO; Martin LL
    Biochem Pharmacol; 2005 May; 69(10):1533-41. PubMed ID: 15857618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.
    Zhou YH; Zheng QC; Li ZS; Zhang Y; Sun M; Sun CC; Si D; Cai L; Guo Y; Zhou H
    Biochimie; 2006 Oct; 88(10):1457-65. PubMed ID: 16740353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies.
    Banu H; Renuka N; Vasanthakumar G
    Biochimie; 2011 Jun; 93(6):1028-36. PubMed ID: 21356265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ile115Leu mutation in the SRS1 region of an insect cytochrome P450 (CYP6B1) compromises substrate turnover via changes in a predicted product release channel.
    Wen Z; Baudry J; Berenbaum MR; Schuler MA
    Protein Eng Des Sel; 2005 Apr; 18(4):191-9. PubMed ID: 15837716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantum mechanical/molecular mechanical study on the mechanisms of compound I formation in the catalytic cycle of chloroperoxidase: an overview on heme enzymes.
    Chen H; Hirao H; Derat E; Schlichting I; Shaik S
    J Phys Chem B; 2008 Aug; 112(31):9490-500. PubMed ID: 18597525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.
    Locuson CW; Gannett PM; Ayscue R; Tracy TS
    J Med Chem; 2007 Mar; 50(6):1158-65. PubMed ID: 17311370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
    Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
    J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.
    Ahlström MM; Ridderström M; Zamora I
    J Med Chem; 2007 Nov; 50(22):5382-91. PubMed ID: 17915853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative binding models for CYP2C9 based on benzbromarone analogues.
    Locuson CW; Rock DA; Jones JP
    Biochemistry; 2004 Jun; 43(22):6948-58. PubMed ID: 15170332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition.
    Baer BR; DeLisle RK; Allen A
    Chem Res Toxicol; 2009 Jul; 22(7):1298-309. PubMed ID: 19445523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates.
    Sykes MJ; McKinnon RA; Miners JO
    J Med Chem; 2008 Feb; 51(4):780-91. PubMed ID: 18237107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C9 polymorphisms: considerations in NSAID therapy.
    Ali ZK; Kim RJ; Ysla FM
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):108-14. PubMed ID: 19152219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors.
    Ahlström MM; Ridderström M; Zamora I; Luthman K
    J Med Chem; 2007 Sep; 50(18):4444-52. PubMed ID: 17696334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential activation of CYP2C9 variants by dapsone.
    Hummel MA; Dickmann LJ; Rettie AE; Haining RL; Tracy TS
    Biochem Pharmacol; 2004 May; 67(10):1831-41. PubMed ID: 15130760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propene activation by the oxo-iron active species of taurine/alpha-ketoglutarate dioxygenase (TauD) enzyme. How does the catalysis compare to heme-enzymes?
    de Visser SP
    J Am Chem Soc; 2006 Aug; 128(30):9813-24. PubMed ID: 16866538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.